Literature DB >> 16594616

Progress in the development of nucleic acid therapeutics.

A Kalota1, V R Dondeti, A M Gewirtz.   

Abstract

Abnormal gene expression is a hallmark of many diseases. Gene-specific downregulation of aberrant genes could be useful therapeutically and potentially less toxic than conventional therapies due its specificity. Over the years, many strategies have been proposed for silencing gene expression in a gene-specific manner. Three major approaches are antisense oligonucleotides (AS-ONs), ribozymes/DNAzymes, and RNA interference (RNAi). In this brief review, we will discuss the successes and shortcomings of these three gene-silencing methods, and the approaches being taken to improve the effectiveness of antisense molecules. We will also provide an overview of some of the clinical applications of antisense therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16594616     DOI: 10.1007/3-540-27262-3_9

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  2 in total

1.  Targeted cleavage: tuneable cis-cleaving ribozymes.

Authors:  John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-12       Impact factor: 11.205

2.  An improved method for isolation of RNA from rat femur.

Authors:  Alka Khera; Thungapathra MuthuKumarappa; Dheeraj Dumir; Poonam Kanta; Gaurav Kumar; Jaswinder Kalra
Journal:  Int J Biochem Mol Biol       Date:  2022-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.